MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
22nd Century Group ROA Ratio 2011-2026 | XXII
Annual ROA Ratio 22nd Century Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.7 | -69.97 | -511.85 | -52.16 | -6.62 | -38.13 | -38.52 | -10.31 | -16.34 | -41.9 | -60.05 | -71.04 | -212.86 | -254.65 | -56.68 | -50.83 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.62 | -511.85 | -94.41 |
Quarterly ROA Ratio 22nd Century Group
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -29.19 | -32.78 | -54.36 | -62.45 | -42.28 | -155.56 | -157.64 | -167.67 | -144.36 | -153.57 | -49.92 | -46.9 | -32.26 | -43.17 | -38.26 | -37.06 | -23.64 | -36.03 | -33.28 | -38.77 | -38.13 | -34.73 | -41.42 | -43.3 | -38.52 | -41.07 | -18.05 | -15.11 | -10.31 | -3.45 | -15.77 | -11.26 | -16.34 | -21.59 | -27.13 | -33.42 | -41.9 | -47.56 | -52.95 | -49.5 | -60.23 | -70.1 | -67.42 | -69.33 | -71.04 | -170.69 | -161.91 | -173.41 | -149.2 | -166.17 | -35.7 | -112.33 | -91.87 | -111.34 | -140.42 | -172.96 | -92.7 | -19.47 | -46.05 | -27.18 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.45 | -173.41 | -66.5 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-241.53 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-22.19 | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
65.04 | $ 1.73 | 5.18 % | $ 203 M | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M | China |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 31.65 | 2.59 % | $ 2.1 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
-5.17 | $ 94.81 | 2.78 % | $ 22.9 B | Germany |
 |
AstraZeneca PLC
AZN
|
8.97 | - | - | $ 96.9 B |  Britain |
 |
CRISPR Therapeutics AG
CRSP
|
-25.67 | $ 53.52 | 3.74 % | $ 4.81 B |  Schweiz |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-114.6 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-40.14 | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
22.57 | $ 2.68 | 1.13 % | $ 250 M | Israel |
 |
Abcam plc
ABCM
|
-0.8 | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
2071.28 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-35.12 | - | -18.52 % | $ 27.3 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
53.1 | $ 0.78 | 14.04 % | $ 35.6 M | Israel |
 |
Esperion Therapeutics
ESPR
|
-4.87 | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-4.99 | $ 31.66 | 1.18 % | $ 852 M | USA |
 |
Affimed N.V.
AFMD
|
-109.04 | - | -34.95 % | $ 21.5 M | Germany |
|
Forte Biosciences
FBRX
|
-83.81 | $ 22.13 | 0.87 % | $ 287 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-207.62 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-43.36 | - | -7.31 % | $ 87 M | USA |
 |
Galectin Therapeutics
GALT
|
-157.87 | $ 2.72 | -2.69 % | $ 174 M | USA |
 |
Generation Bio Co.
GBIO
|
-56.95 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-121.19 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
Grifols, S.A.
GRFS
|
0.99 | $ 8.08 | 0.9 % | $ 5.49 B |  Spain |
 |
Hutchison China MediTech Limited
HCM
|
26.06 | $ 11.72 | -0.26 % | $ 10.1 B | China |
 |
Cyclacel Pharmaceuticals
CYCCP
|
36.63 | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-102.69 | - | - | $ 384 M | Britain |
 |
Heron Therapeutics
HRTX
|
-7.82 | $ 0.9 | 2.13 % | $ 150 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-36.68 | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
-5.72 | $ 14.76 | -0.87 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-48.33 | - | 5.93 % | $ 314 M | Canada |
 |
InflaRx N.V.
IFRX
|
-82.65 | $ 2.6 | -5.11 % | $ 175 M | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 3.35 | -4.83 % | $ 5.51 M | Israel |